Cerity Partners LLC purchased a new stake in shares of Enhabit, Inc. (NYSE:EHAB – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 871 shares of the company’s stock, valued at approximately $459,000.
Several other hedge funds and other institutional investors have also recently made changes to their positions in EHAB. Northern Trust Corp purchased a new stake in shares of Enhabit during the 2nd quarter valued at about $494,000. Millennium Management LLC purchased a new stake in Enhabit in the 2nd quarter worth approximately $230,000. UBS Group AG increased its holdings in Enhabit by 407,300.0% in the 3rd quarter. UBS Group AG now owns 12,222 shares of the company’s stock worth $171,000 after acquiring an additional 12,219 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in Enhabit in the 3rd quarter worth approximately $9,662,000. Finally, Credit Suisse AG bought a new position in Enhabit in the 3rd quarter worth approximately $686,000.
Enhabit Stock Performance
Shares of Enhabit stock opened at $12.43 on Thursday. The firm has a market cap of $622.74 million, a P/E ratio of -11.10 and a beta of 1.15. The company has a current ratio of 1.62, a quick ratio of 1.62 and a debt-to-equity ratio of 0.77. Enhabit, Inc. has a 12 month low of $10.51 and a 12 month high of $16.99. The stock’s fifty day moving average price is $12.67 and its 200-day moving average price is $12.94.
Analysts Set New Price Targets
A number of research firms have recently commented on EHAB. SVB Securities began coverage on Enhabit in a research report on Tuesday, June 20th. They set an “underperform” rating and a $10.00 target price for the company. SVB Leerink restated an “underperform” rating on shares of Enhabit in a report on Tuesday, June 20th. Credit Suisse Group reduced their target price on Enhabit from $15.00 to $12.00 and set a “neutral” rating on the stock in a research note on Friday, August 11th. Finally, Citigroup reduced their target price on Enhabit from $18.00 to $15.00 in a research note on Friday, May 12th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $14.29.
Check Out Our Latest Stock Report on EHAB
About Enhabit
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Featured Stories
- Five stocks we like better than Enhabit
- What Is WallStreetBets and What Stocks Are They Targeting?
- These Quality Dividend Kings Grow their Dividends the Fastest
- With Risk Tolerance, One Size Does Not Fit All
- 3 Growth Stocks to Buy in September
- Where Do I Find 52-Week Highs and Lows?
- 3 Underappreciated Stocks with Nowhere to Go But Up
Want to see what other hedge funds are holding EHAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enhabit, Inc. (NYSE:EHAB – Free Report).
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.
